O KarXT na cognição de pacientes com esquizofrenia em relação a risperidona: revisão de escopo
DOI:
https://doi.org/10.34024/rnc.2025.v33.19850Palavras-chave:
esquizofrenia, KarXT, xanomeline, trospium, antipsicóticos, Revisão sistemáticaResumo
Introdução. A esquizofrenia é uma condição crônica que impacta a cognição e a qualidade de vida. Embora a Risperidona seja amplamente utilizada, sua eficácia nos déficits cognitivos é limitada. O KarXT, recentemente aprovado, apresenta-se como uma alternativa promissora, com foco na melhora cognitiva e menor incidência de efeitos adversos. Este estudo compara ambos os medicamentos quanto à eficácia e benefícios clínicos. Objetivos. Avaliar as evidências disponíveis sobre a eficácia e segurança do KarXT no tratamento da esquizofrenia, comparando-o com os antipsicóticos convencionais. Método. Foi realizada uma revisão sistemática da literatura, buscando artigos que investigassem o KarXT no tratamento da esquizofrenia. Os resultados foram analisados e sintetizados para fornecer uma visão geral do estado atual da pesquisa. Resultados. Os estudos analisados demonstraram que o KarXT é eficaz na redução dos sintomas positivos e negativos da esquizofrenia, além de melhorar as funções cognitivas. O medicamento apresentou um perfil de segurança favorável, com poucos efeitos adversos graves. Conclusão. O KarXT representa uma nova opção terapêutica promissora para o tratamento da esquizofrenia. Seu mecanismo de ação inovador e sua eficácia em múltiplos domínios sintomáticos sugerem que ele pode melhorar significativamente a qualidade de vida dos pacientes. No entanto, são necessárias mais pesquisas para confirmar e expandir os resultados obtidos até o momento.
Métricas
Referências
1.Costa MASG, Soares GFG, Lisbon LAV, Ribeiro PAP. Esquizofrenia: perspectivas atuais acerca do diagnóstico, tratamento e evolução clínica da doença. Braz J Health Rev 2023;6:61-71. https://doi.org/10.34119/bjhrv6n1-007
2.Soares IVA, Carvalho MRN, Sipauba AJC, Costa ACBC, Coutinho JRA, Sobrinho AAP. Aspectos clínicos e epidemiológicos da esquizofrenia: uma revisão de literatura. Braz J Implantol Health Sci 2024;6:2448-61. https://doi.org/10.36557/2674-8169.2024v6n5p2448-2461
3.Ferreira Junior BC, Barbosa MA, Barbosa IG, Hara C, Rocha FL. Alterações cognitivas na esquizofrenia: atualização. Rev Psiquiatr Rio Grande Sul 2010;32:57-63. https://www.scielo.br/j/rprs/a/PJMk67BWDqwwyBtWLhpcYrd/?format=pdf
4.Oliveira IR. Antipsicóticos atípicos: farmacologia e uso clínico. Rev Bras Psiquiatr 2000;22(suppl 1):38-40. https://doi.org/10.1590/S1516-44462000000500013
5.Wannmacher L. Antipsicóticos atípicos: mais eficazes, mais seguros? Uso Racional de Medicamentos: Temas Selecionados 2004;1:1-6. https://bvsms.saude.gov.br/bvs/publicacoes/HSE_URM_APS_1104.pdf
6.Machado AD, Moulin FS, Paarmann ALR, Maçãs ABO, Morelli SA, Araujo RA, et al. Xanomelina-tróspio (KarXT) no tratamento da esquizofrenia. Rev Foco 2024;17:e6183. https://doi.org/10.54751/revistafoco.v17n9-095
7.Wellcome. New treatment for schizophrenia: Cobenfy. 2024 (Acessado em: 11/12/2024). Disponível em: https://wellcome.org/news/new-treatment-for-schizophrenia-Cobenfy
8.Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med 2018;169:467-73. https://doi.org/10.7326/M18-0850
9.Yohn SE, Sauder C, Paul SM, Brannan SK. Understanding the role of M1 and M4 muscarinic receptors in cognitive circuits: implications for cognitive improvement. Biol Psychiatry 2023;93:S94-194. https://drive.google.com/file/d/1EPm48GZklE3rBeiu19nKOGIoTX_XB-CL/view
10.Komatsu Y, Takehara M, Hart X, Takahashi Y, Hori S, Ueno F, et al. Advancements in non-dopaminergic treatments for schizophrenia: A systematic review of pipeline developments. Pharmacopsychiatry 2024;57:221-31. https://doi.org/10.1055/a-2307-6484
11.Weiden PJ, Breier A, Kavanagh S, Miller AC, Brannan SK, Paul SM. Antipsychotic efficacy of KarXT (xanomeline-trospium): post hoc analysis of Positive and Negative Syndrome Scale categorical response rates, time course of response, and symptom domains of response in a phase 2 study. J Clin Psychiatry 2022;83:21m14316. https://doi.org/10.4088/JCP.21m14316
12.Tsapakis EM, Diakaki K, Miliaras A, Fountoulakis KN. Novel compounds in the treatment of schizophrenia: a selective review. Brain Sci 2023;13:1193. https://doi.org/10.3390/brainsci13081193
13.Kaul I, Sawchak S, Correll CU, Kakar R, Breier A, Zhu H, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet 2023;403:160-70. https://doi.org/10.1016/S0140-6736(23)02190-6
14.Kaul I, Sawchak S, Walling DP, Tamminga CA, Breier A, Zhu H, et al. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial. JAMA Psychiatry 2024;81:749-56. https://doi.org/10.1001/jamapsychiatry.2024.0785
15.Watson C, Cummings J, Grossberg GT, Kang M, Marcus R. Evaluating xanomeline and trospium as a treatment for psychosis associated with Alzheimer’s disease: design of the phase 3, ADEPT-1, relapse prevention study. Int Psychogeriatr 2022;36:93-4. https://doi.org/10.1017/S1041610224002035
16.Miller A, Kavoussi R, Breier A. Xanomeline plus tropsium: Tolerability, Safety, and Cognitive Outcomes in Schizophrenia (M177). Neuropsychopharmacol 2016;42(supl. 1):S530. https://pmc.ncbi.nlm.nih.gov/articles/PMC5149584/pdf/npp2016240a.pdf
17.Vasiliu O, Budeanu B, Cătănescu M. The new horizon of antipsychotics beyond the classic dopaminergic hypothesis—the case of the xanomeline–trospium combination: a systematic review. Pharmaceuticals (Basel) 2024;17:610. https://doi.org/10.3390/ph17050610
18.Vita A, Nibbio G, Barlati S. Pharmacological treatment of cognitive impairment associated with schizophrenia: state of the art and future perspectives. Schizophr Bull Open 2024;5:sgae013. https://doi.org/10.3390/ph17050610
19.Pahwa M, Sleem A, Elsayed OH, Good ME, El-Mallakh RS. New antipsychotic medications in the last decade. Curr Psychiatry Rep 2021;23:87. https://doi.org/10.1007/s11920-021-01298-w
20.Sauder C, Allen L, Baker E, Miller A, Paul S, Brannan S. Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study. Translat Psychiatr 2022;12:491. https://doi.org/10.1038/s41398-022-02254-9
21.Correll C, Angelov A, Miller A, Weiden P, Brannan S. Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia. Schizophrenia (Heidelb) 2022;8:109. https://doi.org/10.1038/s41537-022-00320-1
22.Correll C, Miller A, Sawchak S, Kaul I, Paul S, Brannan S. Safety and efficacy of KarXT (Xanomeline Trospium) in Schizophrenia in the Phase 3, Randomized, Double-Blind, Placebo-Controlled EMERGENT-2 Trial. CNS Spectrums 2023;28:220. https://doi.org/10.1017/S1092852923001360
23.Sutera N. Xanomeline-Trospium in schizophrenia: A detailed review and comparison with the Institute for Clinical and Economic Review's analysis. J Manag Care Spec Pharm 2024;30:629-32. https://doi.org/10.18553/jmcp.2024.30.6.629
24.Kidambi N, Elsayed O, El-Mallakh R. Xanomeline-Trospium and Muscarinic Involvement in Schizophrenia. Neuropsychiatr Dis Treat 2023;19:1145-51. https://doi.org/10.2147/NDT.S406371
25.Spoelstra S, Visser L, Knegtering H. Muscarine 1- en/of 4-receptoragonisten als potentieel nieuwe behandeling voor psychosen. Tijdschrift voor Psychiatrie 2023;65:555-62. https://www.tijdschriftvoorpsychiatrie.nl/nl/artikelen/article/50-13243_Muscarine-1-en-of-4-receptoragonisten-als-potentieel-nieuwe-behandeling-voor-psychosen
26.Brannan S, Sawchak S, Miller AC, Lieberman J, Paul S, Breier A. Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia. New Eng J Med 2021;384:717-26. https://doi.org/10.1056/NEJMoa2017015
27.Dean B, Bakker G, Ueda H, Tobin A, Brown A, Kanaan R. A growing understanding of the role of muscarinic receptors in the molecular pathology and treatment of schizophrenia. Front Cell Neurosci 2023;17:1124333. https://doi.org/10.3389/fncel.2023.1124333
28.Paul S, Yohn S, Brannan S, Neugebauer N, Breier A. Muscarinic Receptor Activators as Novel Treatments for Schizophrenia. Biol Psychiatr 2024;96:627-37. https://doi.org/10.1016/j.biopsych.2024.03.014
29.Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int 2014;2014:1-6. https://doi.org/10.1155/2014/656370
30.Mathews M, Adetunji B, Mahmud J, George V, Thomas M, Joseph S. Long-acting risperidone in the treatment of schizophrenia: an evidence-based approach. Psychiatry (Edgmont) 2005;2:36. https://pmc.ncbi.nlm.nih.gov/articles/PMC3004719/
31.Abou-Setta AM, Mousavi SS, Spooner C, Schouten JR, Pasichnyk D, Armijo-Olivo S, et al. First-generation versus second-generation antipsychotics in adults: comparative effectiveness. Rockville: Agency for Healthcare Research and Quality (US); 2012; Report No.: 12-EHC054-EF. https://www.ncbi.nlm.nih.gov/books/NBK107237/
32.Hasan AH, Abid MA. Cobenfy (xanomeline-trospium chloride): a new frontier in schizophrenia management. Cureus 2024;16:e71131. https://doi.org/10.7759/cureus.7111
33.Rattehalli RD, Zhao S, Li BG, Jayaram MB, Xia J, Sampson S. Risperidone versus placebo for schizophrenia. Cochr Database System Rev 2016;12:CD006918. https://doi.org/10.1002/14651858.CD006918.pub3
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2025 Helena Rodrigues Priori, Julia Barbosa de Araujo Fava, Julia Farias Amancio, Mariana Clarindo Albuquerque Bandim, Rudá Leite Marques de Sa Souza, Karolyna de Oliveira Ramos, Hugo Rafael Souza e Silva
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
